Introduction
Epilepsy is a common pediatric neurological disorder with increased risk of developmental delay, autism and psychiatric illness, for which treatment is ineffective in 30-40% of patients.
High-throughput sequencing technologies, including whole-exome sequencing (WES) and epilepsy gene panels, have advanced our genetic understanding as pathogenic variants have been identified in 10-78% of select patients (1) (2) (3) (4) (5) (6) . A genetic diagnosis of epilepsy may enable more accurate counseling regarding prognosis and recurrence risk, avoids unnecessary medical investigations and may change care. It also allows families to connect with the same genetic condition and/or join support groups. Recent studies have demonstrated the potential cost savings of WES in the diagnostic work-up of children with suspected monogenic disorders (7) (8) (9) (10) . However, in Canada, access to such technology in clinical care is variable. In this British Columbia study, we assess the effectiveness of using WES by comparing diagnostic yield, time to diagnosis, and cost to current clinical practices. The potential treatment impact of a genetic diagnosis is also described.
Methods

Patients
Fifty patients with epilepsy (11) were enrolled between December 2014 and June 2015. All had seizure onset at ≤5 years of undefined cause after EEG, brain MRI and chromosome microarray investigations. Seizure types and electroclinical syndromes were classified according to the International League Against Epilepsy (ILAE) (12) . Patients with self-limiting benign electroclinical syndromes, such as Childhood Absence Epilepsy (onset >4 years), were excluded as they most likely have multifactorial inheritance. Patients were classified as retrospective (n=37), defined as an epilepsy diagnosis >6 months before study enrollment with a standard clinical approach to genetic testing (variable genetic tests which include gene-by-gene approach using Sanger sequencing (n=15), small epilepsy gene panels using high-throughput sequencing (n=4), and/or mitochondrial DNA sequencing (n=4)); or prospective (n=13), which included an epilepsy diagnosis <6 months before study enrollment date and having limited to no genetic testing. Varying degrees of screening tests for inborn errors of metabolism; such as plasma amino acids, lactate and ammonia, was also performed in both groups. Clinical data was recorded using a secure Research Electronic Data Capture (REDCap)(13) information system hosted at Child and Family Research Institute.
This study was approved by the BC Children's Hospital and University of British Columbia Ethics
Board. Informed consent and/or assent were obtained before study inclusion.
Whole-exome sequencing
Genomic DNA was extracted from peripheral blood lymphocytes following standard protocols.
Exonic regions were captured using the Ion AmpliSeq Exome Kit (57.7Mb) and WES was performed on an Ion Proton TM according to manufacturers' recommendations (Life Technologies Inc., CA) within 2 weeks of receiving samples. Reads were aligned against the human reference genome hg19. Variant annotation was performed with ANNOVAR (14) integrating data from PHAST PhyloP (15) , SIFT (16), Polyphen2 (17), LRT (18) and
MutationTaster (19) algorithms, Combined Annotation Dependent Depletion (CADD) scores (20) , dbSNP (www.ncbi.nlm.nih.gov/SNP/), the Exome Aggregation Consortium (ExAC; exac.broadinstitute.org) and ClinVar (21)(www.ncbi.nlm.nih.gov/clinvar). Additionally, variants were compared to an in-house database containing more than 900 exomes to exclude platform artifacts and common variants not present in public databases. Analysis was restricted to 565 genes previously implicated in epilepsy ( Supplementary Table 1 and heterozygous variants with MAF <0.1% were reported. All samples were required to meet minimum quality standards, with a WES average coverage >80X.
Sanger sequencing, performed as previously described (22) , was used on a case-specific basis in a few individuals with very specific clinical phenotypes to complete regions of poor coverage in genes related to the patient's phenotype when no candidate variants were identified, or when a heterozygous and potentially pathogenic variant was identified in gene previously implicated in autosomal recessive disease. No additional variants were identified though post-WES Sanger sequencing.
Variant prioritization and validation
Cases were reviewed at a bi-weekly meeting by a multi-disciplinary genomic team. Variant prioritization was performed based on: 1) frequency in public databases; 2) predicted protein impact; 3) disease inheritance, and; 4) correlation of patient phenotype and candidate gene literature. Up to 3 putative causative variants were validated by Sanger sequencing in patient and parental samples. Clinical Sanger sequencing confirmation and interpretation in accordance with ACMG guidelines (23) allowed disclosure to families and management adjustments when indicated. Two time intervals were measured: 1) from a clinical diagnosis of epilepsy to Sanger validation of a putative pathogenic variant; and 2) from enrollment with genetic counselling to Sanger validation of same.
Genetic Counseling and Treatment Implications
Pre-and post-test genetic counseling was performed for each patient/family. As only a limited set of 565 genes related to seizure disorders were annotated, and only in affected probands, reporting related to incidental (secondary) findings was uncommon (24) . Genetic disorders with specific therapeutic implications (47 genes) were defined as conditions in which current literature supports a preferred antiepileptic medication and/or approach (25) (26) (27) .
Cost Estimation
Resource use data were retrospectively acquired from electronic health records and medical charts. Cost estimates in Canadian dollars were based on micro-cost information from the 
Data Analysis
All categorical and quantitative variables were analyzed using STATA (Release 13, College Station, TX).
Results
Targeted WES was performed on 50 patients and clinical features are summarized (Supplementary Table 2 ). The average age of epilepsy onset was 19 months (range 0.2-60 months), 18 months for prospective cases (n=13) and 19 months for retrospective cases (n=37)( Table 1) . Of the 565 genes, 90% had at least 85% of their consensus-coding region sequenced with >20X coverage (Supplementary Table 1 ).
Diagnostic Yield
A definite or likely diagnosis was made in 17/50 patients (34%). A possible diagnosis was identified in another 9 (18%)(Supplementary Table 3 ). Eight of 17 patients (47%) were given a definite or likely diagnosis with potential treatment implications (Table 1) . Pathogenic variants were identified in 15 genes and the majority were the result of de-novo mutations (12/17). The diagnostic yield was higher in the prospective (54%) than retrospective group (27%). Patients in whom a diagnosis was made had earlier onset epilepsy (mean 8.6 vs 27 months, t-test p-value<0.001), and global developmental delay and/or intellectual disability were more common (Table 3) . Of 27 patients with epileptic encephalopathy a definite or likely pathogenic variant was identified in 12 (44%)( Supplementary Table 4 ).
Treatment implications
A genetic disorder with specific therapeutic implications was diagnosed in eight patients (4 prospective and 4 retrospective). Clinical information, treatment changes, and impact are summarized ( Table 2) . Variants in SCN5A, incidental to patient phenotype but with treatment implications, were identified in 2 individuals (001, 067)(Supplementary Table 3 ). SCN5A mutations are implicated in cardiac arrhythmias with sudden death and, rarely, epilepsy (OMIM 300163). Both patients were evaluated by a Cardiologist and no abnormalities were found.
Comparative time to diagnosis
The mean time to genetic diagnosis, from study enrolment with genetic counselling to research validation of the variant was 38 days (20-70) for the prospective group, 48 days (26-105) for the retrospective group, and 44 days (21-105) overall. The mean time from epilepsy diagnosis to research validation of genetic diagnosis was 143 days (42-242) for the prospective group, and 2,172 days (42-6,040) or ~6 years for the retrospective group.
Cost Analysis
Point estimates and 95% confidence intervals, based on bootstrapped standard errors (1000 times with replacement) for each category of diagnostic test by cohorts, were calculated ( Table 5 ). The difference in mean total cost related to the diagnosis of epilepsy for prospective ($4,524) and retrospective ($8,344) groups, exceeds the cost of our diagnostic alternative ($3,234). The potential average savings of targeted WES in the diagnostic workup constitute $1,290 per prospective patient and $5,110 per retrospective patient.
Interpretation
Studies have supported high-throughput panel sequencing as a first-tier testing approach over similarly targeted WES for several diseases based on diagnostic yield, coverage, and costsavings (7, 28) . However, a recent comparative coverage analysis limited to disease-causing variants identified through panels demonstrated that targeted WES detects ≥98.5% of those mutations (29) , and that both approaches have comparable diagnostic yield. A major advantage of WES over panels is the ability to sequence the entire coding genome. Such comprehensive assessment can facilitate re-analysis for novel genes as they are implicated (in the course of this study ~7 genes were identified in seizure disorders and could be examined). Panel sequencing cannot include such contemporary targets.
The clinical utility of targeted WES with Sanger validation (limited ≤3 variants/exome) is supported by the identification of a definite or likely diagnosis in 17/50 (34%) patients and a possible diagnosis in an additional 9/50 (18%)( Table 1) . A higher yield was found in the prospective group with new-onset epilepsy and supports earlier testing, though the number of patients is small. The retrospective group had already undergone extensive clinical testing that was non-diagnostic. Nevertheless, our ability to still identify a genetic diagnosis supports the technology's superior resolution, while related data on phenotypes, management and outcomes may yet inform clinical practice.
The diagnostic yield in our study is comparable to previous findings (2) (3) (4) (5) (6) 30) . Most variants were de-novo and the genetic causes identified were heterogeneous, with recurrent variants only identified in KCNQ2 ( Table 2 ). In a comparable cohort, positive results were identified by WES in 112/293 (38.2%) epilepsy patients (30) . We concur that the diagnostic yield is likely affected by the characteristics of the group studied, sample size, platform used (gene panel or WES) and the timing of the study, given ongoing gene discoveries in epilepsy. In our study, patients with a genetic diagnosis were younger and more likely to have global developmental delay/intellectual disability compared to patients in which no genetic cause was found. Similar to a prior study (30) , our patients with epileptic encephalopathies had a high rate of positive findings (44%).
Our results support the feasibility of targeted WES to rapidly provide clinically-confirmed genetic diagnoses in early-onset epilepsy. Time to Sanger sequencing validation from enrollment averaged 6 weeks which is similar to the 6-8 week turn-around-time quoted by most commercial testing labs. However, this estimate did not include the additional time required to obtain provincial government approval, on a case-by-case basis, to fund WES.
A timely genetic diagnosis is important when considering the potential for treatment impact and optimization of patient outcomes. For the seventeen patients with a genetic diagnosis, eight (47%) were identified to have a disorder with specific treatment implications; for all eight patients, an immediate change in medical management was made ( Table 2 ). The number of genetic disorders identified to have specific treatments implications is likely to grow with ongoing advances in precision medicine.
In British Columbia, the average savings are estimated to be between $1,290 and $5,110 per patient, depending on whether they are new prospective referrals or retrospective. Of note, price estimates reflect academic and/or hospital costs rather than commercial costs, which are 1-5X higher. The Canadian sequencing costs cited are comparable to previous reports but will decrease as even higher throughput sequencing technologies become accessible (7) (8) (9) (10) .
Current healthcare cost estimates are also conservative as patients without a genetic diagnosis will undoubtedly require additional clinic visits and inpatient hospital stays, including epilepsy monitoring unit admissions related to finding the cause of their condition. Of note, a targeted WES approach did not lead to a substantial increase in referrals for incidental findings. Overall, our findings show targeted WES may provide an effective end to an otherwise invasive, time consuming and costly diagnostic odyssey, with societal and economic benefits. Our results also support WES implementation beyond early-onset epileptic encephalopathies, as we have examined a larger and more diverse group of children (10) .
Limitations and strengths
Our study has several limitations, including small sample size although our diagnostic yield is comparable to previous studies (30) . Incomplete coverage of the 565 genes analyzed was partially addressed as outlined in the methods. Proband-parent trio-based WES analyses were not used primarily for financial reasons. Analysis was restricted to 565 epilepsy genes, rather than the entire exome, to identify a genetic diagnosis as quickly as possible and to minimize secondary findings. Assessing relevance of secondary findings and proving pathogenicity of variants in novel candidate epilepsy genes is costly; thus, this approach was taken to maximize patient care and minimize cost. WES data from patients with initial negative results continues to be periodically reviewed for variants in newly described epilepsy genes. In subsequent WES trio analysis, a subset of families has helped identify novel genetic etiologies (31) .
Although almost half of the diagnoses had treatment implications, the long-term impact on clinical outcome following genetically-informed therapeutic interventions is unknown. Early diagnosis and early intervention are important, but advances in precision medicine are also required.
The methods employed for cost analysis cannot replace a prospective randomized controlled trial (RCT) and may not have accurately assessed or included all healthcare costs related to an epilepsy diagnosis. However, an RCT assessing the effect of WES testing on healthcare costs is not yet a practical consideration. Our estimates are not a perfect or a complete description of the current diagnostic work-up, as test records are scattered across different electronic health records systems and paper charts. Data collation within an accessible unified health electronic record would help identify where additional savings are possible. In this study, indirect costs, and the psychosocial impact on the child and family were not measured.
Conclusion/Summary
Targeted WES with limited Sanger sequencing validation is a rapid and minimally invasive test with potential to save costs within the Canadian healthcare system. An early genetic diagnosis may improve a patient's clinical outcome and quality of life. Further research on larger cohorts is warranted to inform diagnosis, clinical outcome and precision medicine. Acknowledging the limitations of our study, targeted WES with Sanger sequencing validation substantially improves current practice and is recommended as the dominant diagnostic strategy. a We excluded individuals with variants of unknown significance or possible genetic diagnosis (9) . b t-test p-value <0.001, c Treatment resistant refers to failure to respond to 2 or more appropriate anti-seizure medications. GDD/ID=Global Developmental Delay/Intellectual Disability.
